INTERVIEWS

Neurosurgeon, Dr.Theresa Williamson talks about her presentation on Simplifying Surgery: Augmented Reality in Complex Spinal Procedures, which addresses the use of augmented reality guide spine surgery and was presented at the 2022 AANS conference. 

In this episode, Lindsay Davis, HCM advocate and former Miss Ohio, shares her experience being diagnosed with hypertrophic cardiomyopathy (HCM) on the heels of the recent FDA approval of Camzyos, which is the first and only cardiac myosin inhibitor treatment that specifically targets the source of obstructive HCM. She also discusses why it’s so important for people to speak to their doctors if they are experiencing symptoms that may be related to HCM or if they have a family member diagnosed with HCM.

Returning guest, Dr. David Hanscom, MD, an orthopedic complex spinal deformity surgeon​ discusses his new book “Do You Really Need Spine Surgery?” He is the author of the book “Back in Control” and has helped people around the world with the method he developed called The DOC (Direct your Own Care) Journey to go pain-free. 

Jeff Bullard, MD, Chief Medical Officer and Chief Product Strategy Officer for Catalyst Health Group, primary care providers, discusses the importance of integrating  pharmacists into care coordination  teams and how a team-based approach  can help improve medication adherence and overall patient health.   He explains how this approach helps improve primary care and deepens relationships between health professionals and patients.   

Robert Kaul, CEO, Founder, and President and Dr. Sonny Kohli, Co-founder and Chief Medical Officer at Cloud DX discuss the recently launched Cloud XR division to deliver the ‘Clinic of the Future’ Augmented Reality platform. Leveraging Cloud DX’s patented VITALITI, modern-day medical Tricorder technology that won the company XPRIZE honors, Cloud XR’s ‘Clinic of the Future’ demonstrates how the Vitaliti™ continuous monitoring device displays real-time patient information in the form of 3-D holographic images. The ‘Clinic of the Future’ is the Medical Metaverse in action, a fully remote, touchless, seamless method enabling healthcare professionals to interact with patients. 

Sapna McManus, MD, MHA, Head of Patient Inclusion and Health-Equity in Genentech’s Chief Diversity Office discusses key insights from the company’s latest D&I report, D&I in biotech, STEM, and progress overall for women and BIPOC employees. This year, Genentech focused on laying the groundwork and building a foundation that will help advance inclusive research, foster belonging and transform society in the years to come. 

Eusebio Carmona, Global Pricing and HEOR Senior Manager at Debiopharm, a biopharmaceutical company based in Switzerland focused on drug development in oncology and bacterial infections, discusses the impact of digital and technology innovations in life sciences, health economics, health data, as well as broad industry trends. 

Michael Clark, CEO of DeliverHealth, a global provider of technology-enabled solutions for hospitals, health systems, and group practices discusses the company’s recent acquisition of PresidioHealth, a healthcare technology and clinical intelligence company, as well as the launch of the DeliverHealth platform. He also talks about DeliverHealth’s founding story, the success the company has had over the past year, and how the company plans to grow and expand in the healthcare market. 

Dr. Pamela Habib, Head of US Medical Affairs, Bayer Radiology and Dr. David Schacht, Breast Radiologist at Northwestern’s Lynne Sage Breast Center at Prentice Women’s Hospital discuss dense breasts and how that can increase the risk for breast cancer.   They also talk about a new survey released by Bayer that indicates gaps in knowledge among women with dense breasts and the need for education.   

Daphne Chan, PhD, MHEcon, Head of Dermatology Medical Affairs at Janssen discusses a first-of-its-kind, large-scale clinical study in dermatology 100 percent dedicated to Black, Hispanic, Asian, Indigenous, and other people of color living with moderate to severe plaque psoriasis (PsO). This Phase 3b VISIBLE study was designed to help create a more diverse and equitable clinical research standard, including new approaches to enrollment and retention, broader community engagement, and new data components.